瑞德西韦在不同程度肾功能不全参与者中的临床药代动力学与安全性
这项I期开放标签平行组研究评估了瑞德西韦及其代谢物在不同程度肾功能不全参与者中的药代动力学与安全性。结果显示瑞德西韦血浆暴露不受肾功能不全影响,但代谢物GS-704277和GS-441524的AUC随肾功能下降而升高。瑞德西韦在肾功能不全参与者中总体安全且耐受良好,支持无需调整剂量用于任何程度肾功能不全患者。
要点
- 瑞德西韦AUC在轻度至严重肾功能不全或肾衰竭中几何均值比范围为0.8至1.2。
- GS-704277的AUC在肾功能不全参与者中最高升高2.8倍,GS-441524最高升高7.9倍。
- 瑞德西韦在肾功能不全参与者中安全且耐受良好,未发现新的安全信号。
核心结论
- 瑞德西韦及其代谢物在肾功能不全参与者中的药代动力学与基于已知消除途径的预期变化一致。
- 瑞德西韦在肾功能不全参与者中总体安全且耐受良好,未发现新的安全问题。
- 结合III期研究结果,支持瑞德西韦用于任何程度肾功能不全患者且无需调整剂量。
研究设计与样本
- I期、开放标签、平行组研究,纳入轻度(n=12)、中度(n=11)、严重(n=10)肾功能不全或肾衰竭(透析n=6,非透析n=4)参与者,并设健康匹配对照。
- 瑞德西韦单次静脉给药:轻度和中度肾功能不全100 mg,严重肾功能不全及肾衰竭透析前40 mg,肾衰竭透析后及非透析20 mg。
主要发现
- 瑞德西韦血浆药代动力学不受轻度、中度或严重肾功能不全或肾衰竭影响,AUC几何最小二乘均值比为0.8至1.2。
- GS-704277的AUC在肾功能不全参与者中最高升高2.8倍,GS-441524的AUC最高升高7.9倍。
- 不良事件和实验室异常与瑞德西韦现有安全性特征一致。
临床怎么用
- 对于任何程度肾功能不全的COVID-19患者,包括透析患者,使用瑞德西韦无需调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Remdesivir is a nucleotide analog prodrug approved for the treatment of COVID-19. This study evaluated the pharmacokinetics and safety of remdesivir and its metabolites (GS-704277 and GS-441524) in participants with varying degrees of renal impairment. Results of this phase I study, along with those of a phase III study, contributed to an extension of indication for remdesivir in the USA and Europe for use in patients with COVID-19 with all stages of renal impairment, including those on dialysis, with no dose adjustment. METHODS: This phase I, open-label, parallel-group study enrolled participants who had mild (n = 12), moderate (n = 11), or severe (n = 10) renal impairment or kidney failure (n = 6 with dialysis, n = 4 without dialysis). Healthy matched controls were enrolled as reference. Remdesivir was given as single intravenous doses of 100 mg (mild and moderate renal impairment), 40 mg (severe renal impairment, kidney failure predialysis), and 20 mg (kidney failure postdialysis and without dialysis). RESULTS: Plasma pharmacokinetics of remdesivir were not affected by mild, moderate, or severe renal impairment or kidney failure. Geometric least squares mean ratios ranged from 0.8 to 1.2 for remdesivir area under the plasma concentration-time curve (AUC). GS-704277 AUC was up to 2.8-fold higher and GS-441524 AUC up to 7.9-fold higher in participants with renal impairment. Adverse events and laboratory abnormalities were consistent with the existing safety profile for remdesivir. CONCLUSIONS: Observed pharmacokinetics for remdesivir and its metabolites in participants with renal impairment aligned with expected changes based on known routes of elimination. Remdesivir was generally safe and well tolerated in participants with renal impairment, and no new safety concerns were identified. These results, along with those from the phase III study in patients with COVID-19 with severely reduced kidney function, support the use of remdesivir in patients with any degree of renal impairment with no dose adjustments. TRIAL REGISTRATION: EudraCT no. 2020-003441-10; 9 July 2020.
引用
- Zhang H, Humeniuk R, Regan S, et al. Clinical Pharmacokinetics and Safety of Remdesivir in Phase I Participants with Varying Degrees of Renal Impairment. Clin Pharmacokinet. 2024. PMID: 39562399. doi:10.1007/s40262-024-01453-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。